As a new-type foreign trade service provider driven by both technology transformation and foreign trade services, HiSiaddi has established a service system of "1+2+3+4=1", which can supply original-source Ticagrelor advanced intermediates from multiple well-known brands. With over a decade of market experience and technological transformation cooperation with manufacturers, HiSiaddi possesses extensive expertise in product compliance issues. Below is HiSiaddi’s case on resolving compliance risks for Ticagrelor advanced intermediates.
If you wish to consult further compliance issues for Ticagrelor advanced intermediates, please contact HiSiaddi customer service.
The client is Medix GmbH, a high-end pharmaceutical group headquartered in Munich, Germany, specializing in novel cardiovascular and metabolic disease drugs and high-end generics distributed across the entire EU plus Switzerland, Norway and other European Economic Area countries. All operations comply with EMA, FDA and ICH Q7/Q11 quality and compliance standards. Its core product is high-purity Ticagrelor API for hospital injectables and premium oral formulations, with an annual procurement volume of 250kg for Ticagrelor advanced intermediates, representing a typical European mid-to-high-end client.
This is the client’s first procurement of the intermediate from China, with core requirements including EMA registration and on-site audit clearance, FDA DMF filing, EU REACH registration, full China export regulatory compliance and full end-to-end batch traceability. Initial cooperation with 3 domestic manufacturers triggered five major compliance crises, resulting in cargo detention, suspended registration and elevated audit risks. The client urgently entrusted HiSiaddi with full resolution within 28 days to ensure smooth customs clearance, audit clearance and establishment of a long-term compliant system.
1.
Missing Qualification Documentation Blocking EMA Registration & Audits Manufacturers only provided basic GMP certificates and COA, lacking CEP certificates, ASMF files, FDA DMF filing numbers, ICH Q7 compliance statements, process validation reports and impurity traceability reports. EMA mandates complete production batch records, cleaning validation reports, stability data and specialized chiral impurity analysis for advanced intermediates; incomplete documentation results in direct registration rejection and automatic failure of on-site audits.
2.
3.
Uncompleted EU REACH Registration Exposes Cargo to Return Risks Ticagrelor intermediates qualify as REACH Substances of Very High Concern (SVHC), requiring full REACH registration, 16-section full-English Safety Data Sheets (SDS) and GHS-compliant labels. The original manufacturers lacked valid REACH registration, leading to detention of the first 50kg shipment by German customs. Customs issued a 7-day deadline for supplementary documentation with penalties and mandatory return of goods as consequences for non-compliance.
4.
5.
Gaps in China Export Compliance Prevent Issuance of Pharmaceutical Export Certificates Manufacturers’ pharmaceutical production licenses did not cover this intermediate, export filings were outdated and complete three-waste discharge environmental reports were unavailable. Without a Pharmaceutical Export Certificate issued by NMPA, customs declaration and outbound shipment are prohibited.
6.
7.
Mismatched Quality Standards with EU & US Pharmacopoeias Trigger Impurity Non-Compliance Manufacturers operated against internal enterprise standards unaligned with EP 10.0 and USP 43. Chiral purity only reached 99.5% (vs. ≥99.8% requirement), single impurity hit 0.15% (vs. ≤0.05% limit) and heavy metals measured 12 ppm (vs. <5 ppm standard). Trace genotoxic impurities (GTIs) were detected with no GTI risk assessment reports, which are zero-tolerance during EMA audits.
8.
9.
Broken Batch Traceability Systems Fail FDA/EMA End-to-End Traceability Mandates Incomplete batch records, missing key process parameters, untraceable raw material sources and test data lacking electronic signatures at manufacturers. EU and US regulators mandate full end-to-end traceability from raw materials to finished goods, tamper-proof data and electronic batch records compliant with 21 CFR Part 11; the original manufacturers’ systems fully failed these requirements.
10.
1. Compliance Manufacturer Restructuring: Terminated cooperation with the original 3 manufacturers and reselected Hongbo Zhiyuan (Model T-01), a certified supplier with CEP/COS credentials, established track record serving European and American high-end pharmaceutical enterprises and full ICH Q7 compliance, as the exclusive supplier.
2. Full Documentation Compilation: Completed a full set of 18-volume English ASMF files within 10 days, assisted with FDA DMF filing, notarized CEP certificates, ICH Q7 compliance statements, process validation reports, cleaning validation reports, stability data, specialized chiral impurity analysis reports and GTI risk assessment reports.
3. End-to-End Audit Support: Compiled English audit response handbooks, batch record templates and traceability flowcharts, assigning technical specialists to conduct remote pre-audits and accompany on-site regulatory audits to guarantee zero rectification items.
1. Expedited REACH Registration: Collaborated with EU local compliance institutions to complete Ticagrelor intermediate REACH registration within 12 days, obtaining official registration certificates and unique registration numbers.
2. SDS & Label Compliance: Compiled 16-section full-English SDS aligned with the latest GHS standards, covering physicochemical properties, toxicology, emergency handling and transportation specifications. Designed EU-compliant GHS labels marked with REACH registration numbers, hazard identifiers and safety precautionary statements.
3. Customs Liaison for Cargo Release: Submitted registration certificates, SDS, compliant labels and certificates of origin to German customs, securing cargo release within 3 days to avoid penalties and forced return.
1. Manufacturer Qualification Rectification: Assisted Hongbo Zhiyuan in expanding the scope of its pharmaceutical production license, updating export filings, supplementing three-waste environmental discharge reports and obtaining official NMPA Pharmaceutical Export Certificates.
2. Standardized Customs Declaration Documentation: Prepared standardized contracts, commercial invoices, packing lists, customs power of attorney, pharmaceutical export certificates, GMP certificates, COA, MSDS and non-dangerous goods identification certificates. Accurately declared HS code 29335990, purity, chiral indicators and product intended use.
3. Full Customs Tracking: Dedicated specialists monitored customs review, inspection and release procedures with zero abnormalities, ensuring on-time shipment of all goods.
1. Process Optimization & Quality Upgrading: Coordinated manufacturer adjustments to recrystallization processes and chiral separation technology, tightening internal control standards to achieve chiral purity ≥99.9%, single impurity ≤0.03%, total impurity ≤0.1%, heavy metals <5 ppm and non-detectable GTIs.
2. EU & US Pharmacopoeia Alignment: Reconducted all testing per EP 10.0 and USP 43 methodologies, issuing English COA, chromatograms and impurity spectra with third-party testing reports (BV Bureau Veritas) attached to every batch.
3. Quality Assurance Agreement Execution: Signed formal quality assurance agreements defining quality specifications, testing methodologies, non-compliance handling protocols and quality compensation clauses, guaranteeing full EMA/FDA compliance for all batches.
1. Electronic Batch Record Upgrade: Assisted the manufacturer in deploying electronic batch record systems compliant with 21 CFR Part 11, enabling automatic data collection, tamper-proof storage, electronic signatures and full traceability.
2. Standardized Traceability Documentation: Compiled English traceability handbooks, batch traceability flowcharts and standardized templates for raw material traceability reports and process parameter records, ensuring full traceability from raw material intake to finished product delivery.
3. Data Integrity Special Audit: Conducted dedicated data integrity audits to identify risks of data tampering, incomplete records and unauthorized access, issuing audit reports and rectification plans to fully align with EU and US data integrity requirements.
1.
Complete Qualification & Documentation Pass EMA/FDA Reviews Without Supplementary Filings Full ASMF, DMF, CEP and ICH Q7 documentation submitted to EMA with zero supplementary information requests and direct registration pre-approval. FDA DMF filing numbers were successfully issued for direct linkage to the client’s ANDA applications.
2.
3.
Customs & Logistics: Detention Lifted, Smooth Clearance & On-Time Delivery German customs formally released the detained 50kg first shipment with no fines or return orders. Subsequent four shipments totaling 200kg all passed customs declaration and EU border clearance without incident, delivered 3 days ahead of scheduled timelines.
4.
5.
Quality & Impurity Indicators Fully Compliant, Exceeding EU & US Pharmacopoeia Benchmarks Actual test results: Chiral purity 99.92%, single impurity 0.02%, total impurity 0.06%, heavy metals 3 ppm, non-detectable GTIs, all superior to client specifications. Third-party BV testing confirmed full compliance, with no quality objections raised during EMA on-site audits.
6.
7.
Traceability & Audit Systems Fully Mature, One-Time EMA Audit Clearance The full end-to-end traceability system passed EMA regulatory audit with high recognition of data integrity, electronic batch records and traceability workflows. Zero rectification items issued during the audit, enabling the client to obtain EU manufacturing licenses for Ticagrelor API without delay.
8.
9.
Long-Term Compliance Mechanism Established for Sustained Stable Supply A standardized compliance handbook for exporting Ticagrelor intermediates to Europe and the US was formulated, detailing mandatory documentation checklists, quality specifications, audit key points and risk prevention protocols. Pre-delivery compliance document reviews, quality sampling inspections and traceability verifications are implemented for every batch to prevent recurring compliance risks.
10.
Client Comment from Compliance Director: “HiSiaddi is a true specialist in EU and US pharmaceutical compliance. Within 28 days, they systematically resolved all our compliance challenges spanning qualification documentation, REACH registration, China export customs clearance, quality standard alignment and traceability system construction. The full closed-loop solution enabled risk-free customs clearance and one-time EMA audit clearance, completely eliminating risks of delayed registration and product launch, far exceeding our expectations.”
Deepened Long-Term Strategic Cooperation The client entrusted HiSiaddi with compliance services and procurement for all Ticagrelor series intermediates and intermediates for 3 follow-up anticoagulant drugs under research. HiSiaddi became the client’s exclusive procurement and compliance service provider in China, with annual procurement volume exceeding 8 million EUR. Both parties jointly established a China-EU pharmaceutical intermediate compliance exchange platform to support more high-quality Chinese products entering high-end European and American markets.
For mid-to-high-end European and American clients sourcing Ticagrelor advanced intermediates, compliance represents the primary and highest market access barrier. Core pain points fall into five categories: qualification documentation, REACH registration, China export regulatory compliance, quality standard alignment and traceability systems. Any single gap may trigger registration rejection, forced cargo return, audit failure and delayed product commercialization.
HiSiaddi’s core competitiveness lies in in-depth comprehension of EMA/FDA/ICH Q7 compliance frameworks, full-chain compliant solution capabilities, access to EU compliance resources and integrated manufacturer coordination capacity. Instead of fragmented remedial actions, HiSiaddi delivers systematic diagnosis, standardized implementation and long-term risk prevention, resolving compliance pain points at the source. This guarantees smooth registration, customs clearance, audit clearance and commercial launch for clients while establishing replicable, stable long-term compliance systems, fully embodying the core competitiveness of professional foreign trade service providers focused on compliance empowerment, quality assurance and value co-creation.
If you wish to consult further compliance issues for Ticagrelor advanced intermediates, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
